Summit Therapeutics Inc. (SMMT)
| Market Cap | 14.00B +0.1% |
| Revenue (ttm) | n/a |
| Net Income | -856.09M |
| EPS | -1.12 |
| Shares Out | 797.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,278,037 |
| Open | 17.20 |
| Previous Close | 17.00 |
| Day's Range | 17.14 - 17.70 |
| 52-Week Range | 12.07 - 29.23 |
| Beta | -1.24 |
| Analysts | Buy |
| Price Target | 29.14 (+66.04%) |
| Earnings Date | Oct 19, 2026 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $29.14, which is an increase of 66.04% from the latest price.
News
Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data
As previously reported, Jefferies upgraded Summit Therapeutics (SMMT) to Buy from Hold with a price target of $25, up from $15, ahead of HARMONi-3 progression-free survival data due late this…
Summit Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics (SMMT) to Buy from Hold with a price target of $25, up from $15.
Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results
Summit Therapeutics stock rallied on Thursday alongside clinical trial results from its partner, Akeso.
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Pha...
Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study
Summit Therapeutics (SMMT) noted that its partner Akeso announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared...
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) e...
Summit announces publication of primary analysis results from Phase III HARMONi
Summit Therapeutics (SMMT) announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with pl...
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In ...
Summit Therapeutics upgraded to Market Perform from Underperform at Bernstein
Bernstein upgraded Summit Therapeutics (SMMT) to Market Perform from Underperform with a price target of $11.90, up from $9.80. The firm believes the current share price accurately reflects the risk-a...
Summit Therapeutics falls -8.5%
Summit Therapeutics (SMMT) is down -8.5%, or -$1.13 to $12.22.
Summit Therapeutics upgraded to Market Perform from Underperform at Leerink
Leerink analyst Daina Graybosch upgraded Summit Therapeutics (SMMT) to Market Perform from Underperform with a $13 price target
Summit says Akeso receives marketing authorization in China for ivonescimab
Summit Therapeutics (SMMT) noted that, on August 12, its partner Akeso (AKESF) announced receipt of marketing authorization in China from the National Medical Products Administration for the use of iv...
Summit gets marketing authorization in China for ivonescimab combination
Summit Therapeutics (SMMT) announced receipt of marketing authorization in China from the National Medical Products Administration, or NMPA, for the use of ivonescimab, a novel, potential first-in-cla...
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in...
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Su...
Summit announces expansion of development program for ivonescimab
Summit Therapeutics (SMMT) announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonesci...
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class i...
Summit Therapeutics price target lowered to $15 from $17 at Jefferies
Jefferies lowered the firm’s price target on Summit Therapeutics (SMMT) to $15 from $17 and keeps a Hold rating on the shares, contending that the “key update” in the Q2…
H.C. Wainwright keeps Neutral on Summit Therapeutics after Q2 report
H.C. Wainwright analyst Mitchell Kapoor reiterates a Neutral rating on Summit Therapeutics (SMMT) following the Q2 report. While HARMONi-3 enrollment is complete, slower event rates push the squamous ...
Summit Therapeutics price target lowered to $38 from $45 at Stifel
Stifel analyst Dara Azar lowered the firm’s price target on Summit Therapeutics (SMMT) to $38 from $45 and keeps a Buy rating on the shares. The firm thinks “timing is…
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on Summit Therapeutics (SMMT) to $38 from $40 and keeps a Buy rating on the shares. Management still expect to conduct…
Summit Therapeutics reiterates ‘substantial doubt’ as going concern
Summit Therapeutics (SMMT) reiterated concerns about remaining a going concern in its June quarter SEC filing. The company used the same language in its March quarter earnings filing. Summit said,…
Summit Therapeutics says will need to raise additional capital
In its 10-Q filing, Summit Therapeutics (SMMT) stated: “The Company’s cash and cash equivalents and short-term investments are not sufficient to fund the Company’s planned operations for a period of…
Summit Therapeutics Earnings Call Transcript: Q2 2026
Ivonescimab continues to demonstrate robust clinical efficacy and safety across global phase III trials, with consistent OS benefit in both Asian and Western populations. Financially, the company maintains a strong cash position and is preparing for a potential U.S. launch pending FDA review.